DPP4 Activities Are Associated with Osteopenia/Osteoporosis and Fracture Risk in Newly Diagnosed Type 2 Diabetes
Background. Recent studies have shown the beneficial effect of dipeptidyl peptidase-4 (DPP4) inhibitor on bone turnover in diabetes mellitus. However, little clinical evidence for DPP4 activity in newly diagnosed type 2 diabetes is available. This study was designed to investigate the relationship b...
Saved in:
Main Authors: | Min Qiu, Shuheng Zhai, Da Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2020/8874272 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Osteopenia Metabolomic Biomarkers for Early Warning of Osteoporosis
by: Jie Wang, et al.
Published: (2025-01-01) -
Association between lipid accumulation products and mortality outcomes in patients with osteoporosis and osteopenia
by: Yazhou Liu, et al.
Published: (2025-03-01) -
Osteoporosis and Fragility Fractures in Type 2 Diabetes
by: Iacopo Chiodini, et al.
Published: (2020-01-01) -
DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: Qixian Wang, et al.
Published: (2018-01-01) -
The diagnostic value of the combined application of blood lipid metabolism markers and interleukin-6 in osteoporosis and osteopenia
by: Liping Fan, et al.
Published: (2025-02-01)